Best peptides for hair growth

Peptides keep showing up in hair-loss forums, clinic menus, and serum labels, sold as a gentler path to thicker hair than the old drugs. The honest picture is messier. A few peptides have real lab data and a handful of small human trials behind them, while others ride almost entirely on mouse studies and marketing. This guide walks through the actual evidence for each peptide, grades how strong that evidence is, and shows where it stands next to the two treatments that still anchor the field.

How peptides might work on hair

A hair follicle cycles through three phases. Anagen is the long growth phase. Catagen is a short shutdown phase. Telogen is the resting phase before the hair sheds. In pattern hair loss, follicles spend less time in anagen each cycle and shrink a little more each time. The hair gets thinner, shorter, and finer until it barely grows at all. This slow shrinking is called miniaturization.

Most peptides studied for hair aim at one or more of these targets:

Wnt/beta-catenin signaling. This pathway tells follicle stem cells to wake up and start a new growth cycle. Several hair peptides try to switch it on.
DHT and the androgen receptor. Dihydrotestosterone (DHT) is the hormone that drives pattern baldness. A few peptides claim to blunt its effect on the follicle.
Dermal papilla cells. These cells at the base of the follicle act like a control center for growth. Peptides that help them survive and multiply may keep follicles active longer.
Inflammation and blood supply. Some peptides raise growth factors like VEGF or calm the low-grade inflammation that surrounds struggling follicles.

A peptide hitting one of these targets in a dish is not the same as a peptide regrowing hair on a human head. Keep that gap in mind through the rest of this guide. A 2026 review in Biomedicines surveying short peptides for hair loss reached the same conclusion: the mechanisms are plausible and the early signals are interesting, but the human evidence is thin for nearly every candidate (Overview of Short Peptides for Hair Loss, Biomedicines 2026).

Why "it activates Wnt" is not enough

A lot of peptide marketing stops at the mechanism. The bottle says the peptide "activates Wnt" or "boosts dermal papilla cells," and the reader is meant to fill in the rest. But a mechanism is a hypothesis, not a result. Plenty of compounds light up the right pathway in a petri dish and do nothing useful on a scalp. The path from "switches on Wnt in a cell" to "grows a visible, terminal hair" has many steps, and a compound can fail at any of them.

There are three reasons a promising mechanism can fall apart in real life:

It never reaches the follicle. The skin barrier blocks large molecules, and most peptides are large.
The dose that works in a dish is unreachable on skin. Lab concentrations are often far higher than anything a topical can deliver.
The biology differs between species. Mouse follicles and human follicles cycle differently, and mouse skin is far easier to grow hair on.

This is why the rest of this guide weighs human trials above mechanism stories. A clever mechanism earns a peptide a look. Only human data earns it your money.

The evidence, peptide by peptide

Below is a quick map before the detail. The grade reflects the strength of evidence in humans, not the loudness of the marketing.

Peptide	Main proposed mechanism	Best human data	Evidence grade
Copper peptide (GHK-Cu / AHK-Cu)	Dermal papilla support, Wnt, VEGF, anti-inflammatory	In vitro human follicle data; small/older topical trials; one industry serum	Weak to moderate, mostly topical
Biotinoyl tripeptide-1	DHT modulation, keratinocyte proliferation	Small open-label trials, always inside multi-ingredient lotions	Weak, confounded by other actives
PTD-DBM	Blocks CXXC5, frees Wnt signaling	None (mouse only)	Preclinical only
Thymosin beta-4 (TB-500)	Follicle stem cell activation, anagen induction	None for hair (mouse and in vitro only)	Preclinical only
Valproic acid (paired with peptides)	GSK-3beta inhibition, Wnt activation	One small randomized feasibility trial	Weak but human

Copper peptides (GHK-Cu and AHK-Cu)

GHK-Cu is a copper-binding tripeptide (glycyl-histidyl-lysine plus copper). It is the most-studied hair peptide with actual human tissue behind it. In a 2007 lab study, a tripeptide-copper complex applied to cultured human hair follicles increased the size of the follicles and lengthened the growth phase compared with untreated follicles (Pyo et al., Arch Pharm Res 2007). That is human tissue, but it is still a dish, not a scalp.

AHK-Cu is a man-made cousin engineered to be more stable on the scalp. The marketing for both peptides leans on a commercial topical (Tricomin) from the late 1990s that reported gains in hair density. Those reports are old, the trials were small, and several were tied to the company selling the product. That does not make them worthless. It does mean you should treat the numbers as a starting point, not proof.

What copper peptides have going for them: a believable mechanism (dermal papilla support, more VEGF, less inflammation), a long track record of skin safety, and decent results when delivered topically. What they lack: a large, independent, modern randomized trial showing real regrowth in people. The deeper mechanism story is covered in our GHK-Cu copper peptide research review, and the topical formulations overlap heavily with products in our best peptide serums for skin guide.

One more point on the copper itself. The copper is not decoration. The tripeptide carries copper into the tissue, and copper plays a role in the enzymes that build collagen and remodel the area around the follicle. That is part of why GHK-Cu has broad effects on skin and wound repair, and why the same molecule shows up in both anti-aging skin products and hair serums. It is a real, well-characterized biological actor, which is more than can be said for some peptides on this list.

Bottom line: Copper peptides are the most reasonable peptide to actually try, as a topical, ideally alongside a proven drug rather than instead of one. Evidence is weak to moderate.

Biotinoyl tripeptide-1 (Biotinyl tripeptide-1)

This is a lab-made peptide built around a biotin core. The pitch is that it both nudges keratinocytes in the hair bulb to divide and softens the effect of DHT on the follicle. It shows up in many over-the-counter hair lotions.

Here is the catch, and it is a big one. Every human study of biotinoyl tripeptide-1 puts it inside a cocktail of other active ingredients, like apigenin, oleanolic acid, adenosine, and a minoxidil-like compound. The small open-label trials of these lotions do report better hair density and thickness over a few months. But you cannot pull out how much of that came from the peptide versus everything else in the bottle (see the PubMed record for biotinoyl tripeptide-1 in androgenetic alopecia). No trial has tested the peptide on its own against a real placebo.

Bottom line: Plausible mechanism, but the human evidence is hopelessly tangled with other ingredients. Treat any product claim about this peptide with caution. Evidence is weak.

PTD-DBM

PTD-DBM is one of the most interesting peptides in this space on paper, and one of the least proven in people. The idea is clever. A protein called CXXC5 acts as a brake on the Wnt pathway by grabbing a partner protein called Dishevelled. PTD-DBM is built to slip into the cell, block that grab, and release the brake, which should switch Wnt signaling back on and push follicles into growth.

In a 2017 study from a Yonsei University team, topical PTD-DBM applied to mouse skin produced new hair growth and even regrew follicles in wounded skin, especially when paired with valproic acid (Lee et al., J Invest Dermatol 2017). The results in mice were striking. That is exactly why you have to be careful. Mouse hair biology is not human hair biology, and the list of compounds that regrew hair on mice and then failed in people is long.

As of mid-2026, there is no published human trial of PTD-DBM. None. The peptide is sold by research-chemical vendors with no FDA approval and no human safety data. People do mix it with valproic acid at home based on the mouse paper, which is a clear example of running ahead of the evidence.

Bottom line: Genuinely promising mechanism, zero human data. Preclinical only. Do not confuse a good mouse study with a treatment.

Thymosin beta-4 (TB-500)

Thymosin beta-4 is a small protein the body makes that helps cells move and tissues repair. TB-500 is the synthetic version sold for research. The hair angle comes from older work showing it can wake up hair follicle stem cells.

The cleanest data is from the early 2000s. A 2004 study found that thymosin beta-4 sped hair growth in rats and mice by activating follicle stem cells (Philp et al., FASEB J 2004), and a 2007 follow-up traced this to stem cells migrating and turning into the right cell types (Philp et al., Ann N Y Acad Sci 2007). The mechanism is real and the animal results are consistent.

But notice what is missing: any human hair trial. TB-500 has been studied far more for wound healing and injury than for hair, and even there the human data is limited. We cover that broader picture in our BPC-157 vs TB-500 injury recovery comparison. For hair specifically, all the evidence is in animals and cell cultures. It is also usually injected, which carries more risk than a topical serum and is not something to do on the strength of mouse data.

Bottom line: Solid animal evidence, no human hair trials, and an injection-based delivery that raises the stakes. Preclinical only.

Valproic acid (the peptide partner)

Valproic acid is not a peptide. It is an old epilepsy drug. It earns a spot here because it keeps showing up paired with hair peptides, especially PTD-DBM, and because it has something most of these peptides lack: a small randomized human trial.

The mechanism overlaps with the peptides. Valproic acid blocks an enzyme called GSK-3beta, which in turn activates the Wnt pathway, the same growth switch the peptides chase. A 2012 study showed it regrew hair in mice and boosted activity in human dermal papilla cells (Lee et al., PLoS One 2012).

The human trial is the reason to mention it at all. In a 2014 randomized feasibility study, men with pattern hair loss who used an 8.3% topical valproic acid spray for 24 weeks gained more hairs by phototrichogram than men on placebo (Jo et al., J Dermatol 2014). It was a small study, it was called a "feasibility" study for a reason, and it tested valproic acid alone, not a peptide. Still, it is one of the few human hair-growth signals anywhere in this category.

Bottom line: Not a peptide, but the most common peptide partner, and the one ingredient in the home-mix protocols with an actual small human trial. Evidence is weak but, unusually for this list, human.

How peptides stack up against proven treatments

This is the comparison that matters most, and it is where peptides come up short. Two treatments are approved by the U.S. Food and Drug Administration for pattern hair loss, and both have decades of large trials behind them.

Treatment	Status	Strength of evidence	What it actually does
Minoxidil (topical/oral)	FDA-approved	Strong, many large RCTs	Extends anagen, improves follicle blood supply; modest but real regrowth
Finasteride (oral)	FDA-approved (men)	Strong, long-term data	Blocks DHT; slows loss and regrows hair in most men
Copper peptides	Cosmetic / OTC	Weak to moderate, topical	Supports dermal papilla; may help density
Biotinoyl tripeptide-1	Cosmetic / OTC	Weak, confounded	DHT/keratinocyte effects inside multi-ingredient lotions
PTD-DBM, TB-500	Research chemicals	Preclinical only	Wnt activation, stem cell effects in animals

Finasteride lowers DHT and, in long-term follow-up, most men keep or regain hair on it; its mechanism and risks are spelled out on the FDA-approved finasteride (Propecia) label. Minoxidil produces modest regrowth in a large share of users, and combining the two beats either one alone in meta-analyses of androgenetic alopecia treatment.

No peptide has data anywhere near this. A peptide might one day add to these drugs. Right now, none has earned the right to replace them. If you only do one thing for pattern hair loss, the evidence points to minoxidil, finasteride, or both, not a peptide.

It helps to think in tiers. Tier one is the proven drugs, with large trials and regulatory approval. Tier two is topical copper peptides, with a believable mechanism and weak-to-moderate support, reasonable as an add-on. Tier three is everything still stuck in animals, like PTD-DBM and TB-500, which belong in the lab, not on your scalp. The marketing tends to flatten these tiers into one shelf of "hair peptides." The evidence does not. A treatment with thirty years of human trials and a treatment with zero human trials are not in the same category, no matter how similar the bottles look.

A fair way to read the peptide story is this: these are early-stage ideas, some better than others, none finished. The exciting ones by mechanism are the least proven in people. The most proven in people are barely proven at all. That is not a reason to write peptides off forever, but it is a reason to keep them in their lane behind the drugs that actually work.

Delivery matters more than people think

A peptide that works in a dish still has to reach the follicle. That is harder than it sounds. Peptides are large, water-loving molecules, and the outer skin layer is built to keep exactly those molecules out.

Topical is the best-studied route for hair peptides, especially copper peptides. Penetration is the main limit.
Microneedling with a topical peptide creates tiny channels that help the peptide get deeper, and the micro-injury itself stimulates some growth. This pairing is common in clinics.
Injected (mainly TB-500) skips the skin barrier but adds infection risk, dosing guesswork, and sterility problems, all on top of zero human hair data. The risk does not match the evidence.

If you try a peptide, a topical or a microneedling-paired topical is the more sensible route. Injecting a research chemical into your scalp for hair growth is not supported by anything published.

A realistic protocol view

People often want a dose chart. For hair peptides, an honest chart has to come with a warning: most of these "protocols" are not from controlled trials. They are pieced together from animal studies, vendor instructions, and forum experience. The table below shows how these peptides are typically used and, just as important, how much real human evidence sits behind each use.

Peptide	Common route	Typical use as marketed	Human evidence behind the protocol
Copper peptide (GHK-Cu / AHK-Cu)	Topical serum, often daily	Apply to scalp; pair with microneedling 1-2x/week	Some, but old/small/industry-linked
Biotinoyl tripeptide-1	Topical lotion	Once or twice daily, inside a blended formula	Indirect only; never tested alone
PTD-DBM	Topical (home mix)	Mixed with valproic acid, applied to scalp	None
Thymosin beta-4 (TB-500)	Injection (research)	Weekly injections borrowed from injury dosing	None for hair
Valproic acid	Topical spray (~8.3%)	Applied to scalp over weeks	One small randomized feasibility trial

The pattern is hard to miss. The peptides with the most elaborate "protocols" online, PTD-DBM and TB-500, have the least human evidence. The one entry with an actual randomized trial, valproic acid, is not even a peptide. Treat any confident dosing claim about a hair peptide as opinion until a human trial backs it.

Safety: what we know and what we don't

Topical copper peptides have a long, fairly clean safety record in skin care. Mild irritation or redness is the usual worst case. Biotinoyl tripeptide-1, used topically in cosmetics, is also generally well tolerated.

The bigger safety unknowns are with the research-chemical peptides. PTD-DBM and TB-500 have no human safety trials for hair. They are sold "for research use only," which means no regulator has checked them for purity, dose, or contamination. Quality varies a lot between sellers, a problem covered in our guide to buying peptides legally. Injecting an unregulated peptide adds infection and sterility risks on top of that.

There is also a hormonal wrinkle. Some peptides claim to blunt DHT. If that were strongly true, it could in theory carry side effects similar to DHT-blocking drugs. The peptides almost certainly do not act that strongly, but it is one more reason not to assume "peptide" means "automatically safe."

Who should consider peptides, and who should wait

A reasonable fit for a topical peptide:

You are already using minoxidil and/or finasteride and want to add something with a plausible mechanism and a clean topical safety record. Copper peptides fit here.
You cannot tolerate the proven drugs and want a lower-stakes topical option, knowing the evidence is weak.
You like the idea of pairing a peptide with microneedling, which has its own modest support.

Better to wait:

You want injected peptides (TB-500) or research chemicals (PTD-DBM) for hair. The human evidence does not exist, and the risks are real.
You are hoping a peptide will replace finasteride or minoxidil. Nothing here supports that.
You are early in hair loss and have not yet tried the proven, well-studied treatments. Start with what works.

For people building a broader regimen, peptides are best treated as a possible add-on, not a foundation. Our best peptide supplements guide puts hair peptides in the context of the wider category, where the same pattern repeats: strong marketing, thinner evidence.

The honest summary

Strip away the marketing and three things are true. First, copper peptides have the most credible case among hair peptides, and even theirs rests on old or small or industry-linked trials plus solid lab data. Second, the most exciting peptides by mechanism, PTD-DBM and thymosin beta-4, have no human hair trials at all, only animal studies. Third, no peptide comes close to the evidence behind minoxidil and finasteride, which remain the only treatments actually proven to regrow hair in people.

Peptides for hair are a promising research area, not a finished product. If you try one, make it a topical copper peptide, layer it on top of proven treatment rather than in place of it, and keep your expectations honest.

Frequently Asked Questions

Do any peptides regrow hair as well as finasteride or minoxidil?

No. Finasteride and minoxidil are FDA-approved and backed by large, long-term trials. No peptide has human evidence anywhere near that level. Copper peptides have the most data, but it is weak to moderate and largely topical, not the regrowth proof the approved drugs carry.

Is PTD-DBM proven to grow hair in humans?

No. The strong PTD-DBM results are from mouse studies, including the 2017 Yonsei paper. As of mid-2026 there is no published human trial of PTD-DBM, and it is sold only as a research chemical with no FDA approval or human safety data.

Are copper peptides safe to use on the scalp?

Topical copper peptides have a long, generally clean safety record in skin care, with mild irritation or redness as the usual worst case. They are the most reasonable peptide to actually try for hair, ideally as a topical alongside a proven treatment rather than instead of one.

Should I inject TB-500 for hair growth?

The evidence does not support it. Thymosin beta-4 (TB-500) has animal and cell-culture data for hair but no human hair trials. Injecting an unregulated research chemical adds infection, dosing, and sterility risks on top of that missing evidence.

Why is valproic acid mentioned with hair peptides if it isn't a peptide?

It activates the same Wnt growth pathway many hair peptides target, and it is the common partner in home-mix protocols with PTD-DBM. It is also one of the few ingredients in this category with an actual small randomized human trial, the 2014 topical valproic acid study.

This article is for general information only and is not medical advice. Talk to a licensed dermatologist or physician before starting any treatment for hair loss.